mark bostic

41
Bioterrorism: Are Physician Assistants Prepared to Diagnose and Treat? Mark Bostic Spring 2006 PAS 646

Upload: samueljack

Post on 02-Nov-2014

592 views

Category:

Documents


1 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Mark Bostic

Bioterrorism:

Are Physician Assistants Prepared to Diagnose and Treat?

Mark Bostic

Spring 2006

PAS 646

Page 2: Mark Bostic

Objectives

1) Talk about PA preparedness

2) Talk about bioterroristic diseases

Page 3: Mark Bostic

What is bioterrorism?

Form of terrorism in which biological agents are used to inflict harm and/or fear upon a population.

http://www.fbi.gov/anthrax/images.htm#1

Page 4: Mark Bostic

Physician Assistant Training

Medical school model Consistent with physician training Bioterrorism?

Page 5: Mark Bostic

Bioterrorism Training

Physician Assistant Programs’ Websites– No training specified

Accreditation Review Commission on Physician Assistant Programs (ARC-PA)– No training mandated

Liaison Committee on Medical Education (LCME)– No training mandated

Page 6: Mark Bostic

Physician Assistant Preparedness

Studies lacking for PA’s Physician preparedness

– HHS Agency for Healthcare Research and Quality (AHRQ) survey indicates physicians unprepared

n=614 physicians, 18% trained, 93% expressed interest

– Johns Hopkins University study indicates physicians unprepared

n=2407 physicians, pretest 46.8%, posttest 79% Chickenpox vs. smallpox, botulism vs. Guillain-Barre

Page 7: Mark Bostic

CDC top six bioterroristic agents

Anthrax Smallpox Plague Viral hemorrhagic fevers Botulism Tularemia

Page 8: Mark Bostic

Anthrax

Bacillus anthracis– Spore-forming bacterium

Livestock, meat products, wool sorters Inhalational, cutaneous, gastrointestinal Often misdiagnosed as influenza

Page 9: Mark Bostic

Inhalational anthrax

Most deadly Incubation period Replication and toxin release Phase I: nonspecific constitutional symptoms

– Mild fever, malaise, myalgia, nonproductive cough, emesis, chest/abdominal pain

Phase II: more severe– Higher fever, chest/neck edema, mediastinal

widening, dyspnea, cyanosis, meningoencephalitis, shock

Page 10: Mark Bostic

Diagnosis: inhalational anthrax

Chest x-ray and chest CT– Mediastinal widening, pleural effusion, consolidation

Blood smear and gram stain/culture– Large bacilli– Left shift

Cerebrospinal Fluid– Purulence, decr. glucose, incr. protein, elevated

pressure, blood

Page 11: Mark Bostic

Inhalational anthrax

www.cdc.gov

Page 12: Mark Bostic

Cutaneous anthrax

Most prevalent form of infection Skin barrier must be compromised Replication and toxin release

– May take up to 14 days

Page 13: Mark Bostic

Diagnosis: cutaneous anthrax

1) pruritic papule or pustule surrounded by smaller vesicles

2) mild fever and malaise 3) papule enlarges to a circular lesion

surrounded by edema– Ruptures and necroses– Characteristic “Black Eschar”

Page 14: Mark Bostic

Cutaneous anthrax

www.cdc.gov

Page 15: Mark Bostic

Treatment: anthrax

Combination of:– Ciprofloxacin (Cipro ®)– Doxycycline (Vibramycin ®)

Combination varies depending upon:– Adult, child, immunocompromised

Amoxicillin for pregnant females

Page 16: Mark Bostic

Smallpox (Variola)

DNA virus Transmitted in droplet form Respiratory tract mucosa 12-14 day incubation period Often misdiagnosed as varicella

Page 17: Mark Bostic

Diagnosis: smallpox

Rapid onset of nonspecific sx’s– Fever, HA, malaise, chills, myalgia, anorexia, N/V,

diarrhea, abdominal pain, delirium, convulsions Papules surrounded by rash a few days later Centrifugal distribution Papules pustules crusted lesion Simultaneous staging of lesions Not “dewdrops on a rose petal”

Page 18: Mark Bostic

Smallpox

www.cdc.gov

Page 19: Mark Bostic

Treatment: smallpox

No cure Tx is supportive Vaccination available = Vaccinia

Page 20: Mark Bostic

Plague

Yersinia pestis– Gram negative, pleomorphic coccobacillus– Infects by fleas carried by rodents

Bubonic, septicemic, pneumonic

Page 21: Mark Bostic

Diagnosis: bubonic and pneumonic plague

Onset of nonspecific sx’s in 2 to 6 days– Fever, chills, weakness, malaise, myalgia, lethargy chest pain, dyspnea, watery/bloody expectorated

sputum– Tender buboes (swollen lymph nodes)– 2 to 4 days later, lung exhibits necrosis, infiltration,

hemorrhaging, effusion, abscesses Chest x-ray Hypotension, respiratory distress, pulmonary

edema = death in 24 hours

Page 22: Mark Bostic

Plague

                               

      

www.cdc.gov

Page 23: Mark Bostic

Diagnosis: septicemic plague

Fever, chills, prostration, N/V, abdominal pain Purpura and DIC hypotension, shock, and

death Blood cultures (all types of plague)

– Prior to tx with antibiotics Gram stain & culture (all types of plague)

– Prior to tx with antibiotics Sputum sample

Page 24: Mark Bostic

Treatment: plague

Streptomycin (1st line) Gentamicin (2nd line) Tetracylines such as chloramphenicol

Page 25: Mark Bostic

Viral hemorrhagic fevers

RNA viruses:– Arenavirus, bunyavirus, filovirus, flavivirus

Infection via vectors:– Mosquitoes, ticks, cats, rabbits, people

History should include travel to tropical regions

Page 26: Mark Bostic

Diagnosis: VHF

Onset of nonspecific symptoms:– Fever, HA, myalgia/arthralgia, N/V, diarrhea– Possible bradycardia, tachycardia, liver necrosis,

delirium, confusion, coma Hallmark: generalized systemic coagulopathy

with profuse bleeding– Petechiae, ecchymoses, epistaxis, hematemesis– Bleeding from gingiva, vagina, any puncture sites

Definitive: immunoglobulin Antibody to specific virus

Page 27: Mark Bostic

Viral hemorrhagic fevers

http://www.gata.edu.tr/dahilibilimler/infeksiyon/resimler/VIRAL_HEMORRHAGIC_FEVER/__VIRAL_HEMORRHAGIC_FEVERS_2.JPG

Page 28: Mark Bostic

Treatment: VHF

No FDA approved drugs Ribavirin may be effective Supportive treatment of shock:

– Hydration, blood transfusions, etc.

Page 29: Mark Bostic

Botulism

Spore-forming anaerobic bacterium Clostridium botulinum

Toxin is most lethal of all toxins– 100,000x sarin gas– 15,000x nerve gas

Iraq: enough to kill every human 3 times Bacterium or toxin may be aerosolized, placed

in food supplies Blocks ACh release

Page 30: Mark Bostic

Diagnosis: botulism

Descending paralysis Ptosis, diplopia, blurred vision, and dilated,

sluggish pupils Difficulty speaking, chewing, swallowing Paralytic asphyxiation or flaccid airway collapse Culture serum, stool, gastric contents, suspected

food

Page 31: Mark Bostic

Treatment: botulism (cont.)

Equine botulinum antiserum Antibiotic therapy experimental

– Metronidazole– PCN

Supportive: ventilation and tube feeding

Page 32: Mark Bostic

Tularemia

Nonmotile, aerobic gram negative coccobacillus Francisella tularensis– 2 subspecies: biovar tularensis & biovar palaeartica

Bite of tick, mosquito, handling infected carcass

Aerosolization possible Incubates, then moves to LN and multiplies Pathology at all sites where bacillus spreads

Page 33: Mark Bostic

Diagnosis: tularemia

Site of inoculation: papule-pustule-ulcer pattern Eye: ulceration of conjunctiva with LAD Oral: tonsillitis or pharyngitis with cervical LAD Lungs: bronchiolitis, pneumonitis,

pleuropneumonitis with LAD Fever, abdominal pain, diarrhea, emesis IF, GS&C

Page 34: Mark Bostic

Tularemia

http://phil.cdc.gov/Phil/details.asp

                                 

         

http://www.logicalimages.com/resourcesBTAgentsTularemia.htm

Page 35: Mark Bostic

Treatment: tularemia

Ciprofloxacin or doxycycline (early) Streptomycin or gentamicin (late) No vaccine

Page 36: Mark Bostic

Reporting

Written plan in every health care facility Notify local health care officer for suspected or

confirmed cases

Page 37: Mark Bostic

Conclusion

Data suggest that physicians are unprepared to diagnose and manage diseases of a bioterroristic cause.

Studies need to be performed to determine whether or not PA’s are prepared.

Page 38: Mark Bostic

Thank you for your attention!

Page 39: Mark Bostic

References

ARC-PA (2005). “Accreditation standards for physician assistant education.” Section B(1-7): 11-13.   CDC (2005). “Agents, diseases, and other threats.” Cited on World Wide Web 1 December 2005 at

http://www.bt.cdc.gov/agent/.   Cosgrove, S. E., T. M. Perl, X. Song, S. D. Sisson (2005). “Ability of physicians to diagnose and manage

illness due to category A bioterrorism agents.” Archives of Internal Medicine 165(17): 2002-2006.   Endy, T. P., S. J. Thomas, J. V. Lawler (2005). “History of U.S. Military Contributions To The Study of Viral

Hemorragic Fevers.” Military Medicine 170(4): 77-91.   Goad, J. A., J. Nguyen (2003). “Hemorrhagic Fever Viruses.” Top Emerg Med 25(1): 66-72.   Hickner, J., F. M. Chen (2002). “Survey on Eve of Anthrax Attacks Showed Need for Bioterrorism Training.”

Press release 5 September 2002. Agency for Healthcare Research and Quality, Rockville, MD. Cited on World Wide Web on 22 December 2005 at http://www.ahrq.gov/news/press/pr2002/anthraxpr.htm

  Karwa, M. (2005). “Bioterrorism: Preparing for the impossible or the improbable.” Critical Care Medicine 33(1

Suppl): S75-95.

Page 40: Mark Bostic

References

LCME (2004). “Functions and structure of a medical school.” Section II(A): 2.   Leger, M. M., R. McNellis, R. Davis, L. Larson, R. Muma, T. Quigley, S. Toth (2001). “Biological and chemical

terrorism: Are we clinicians ready?” American academy of physician assistants. Cited on world wide web 3 January 2005 at http://www.aapa.org/

clinissues/BTtext.htm.   Lohenry, K. (2004). “Anthrax exposure – stay alert, act swiftly” Journal of the American Academy of Physician

Assistants 17(8): 29-33.   NPR online, (2005). “History of Biological Warfare.” Cited on World Wide Web 21 November 2005 at

http://www.npr.org/news/specials/response/anthrax/features/2001/ oct/011018.bioterrorism.history.html.   O’Brien, K., M. Higdon, J. Halverson (2003). “Recognition and Management of Bioterrorism Infections.”

American Family Physician 67(9): 1927-34.   Straight, T. M., A. A. Lazarus, C. F. Decker (2002). “Defending Against Viruses in Biowarfare.” Postgraduate

Medicine 112(2): 75-80.

Page 41: Mark Bostic

References

Varkey, P., G. Poland, F. Cockerill, T. Smith, P. Hagen (2002). “Confronting Bioterrorism: Physicians on the Front Line.” Mayo Clinic Proceedings 77(7): 661-72.

  United States Department of Health and Human Services (2002). “HHS announces $1.1 billion in funding to

states for bioterrorism preparedness.” HHS press release 31 January 2002. Cited on World Wide Web 30 December 2005 at http://www.hhs.gov/news/press/

2002pres/20020131b.html.